Last reviewed · How we verify
NEU-411
At a glance
| Generic name | NEU-411 |
|---|---|
| Sponsor | Neuron23 Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease (PHASE2)
- A Study to Assess NEU-411 in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NEU-411 CI brief — competitive landscape report
- NEU-411 updates RSS · CI watch RSS
- Neuron23 Inc. portfolio CI